Archive for : May, 2018

Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)

PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (lurbinectedin, PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.

     (Logo: )

The IDMC”s recommendation came after an analysis of the safety data obtained with more than 500 patients treated in the trial. This pivotal randomized Phase III trial assesses the efficacy of PM1183 in combination compared with the standard treatment for this indication: investigator”s choice of either Topotecan or CAV (cyclophosphamide, doxorubicin, and vincristine).

About Zepsyre® 

Zepsyre® (lurbinectedin, PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

About small-cell lung cancer  

SCLC is a very aggressive cancer that usually presents with distant metastases and has already spread at the time of diagnosis, thus limiting the role of traditional approaches and posing a worse prognosis compared to other lung cancer types. The 5-year survival rate is about 5%[i]. About 18% of all the lung cancer cases diagnosed are SCLC, and only in the US more than 34,000 new cases are recorded every year. This tumor is strongly associated with tobacco smoking, posing an important public health problem[ii]. After failure to treatment with a platinum-based therapy in first line, the therapeutic alternatives are very limited, and the approval of the last drug for this disease took place 20 years ago.

About PharmaMar  

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at


This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.



Media Contact: 

Alfonso Ortín – Communications Director Mobile: +34-609493127
Miguel Martínez-Cava – Digital Communication Manager Mobile: +34-606597464
Phone: +34-918466000

Investor Relations: 
Phone: +34-914444500
Or please visit our website at


MADRID, May 29, 2018 /PRNewswire/ —

Lockton MENA Continues Expansion With New Cairo Office

Lockton Middle East and North Africa (MENA) has continued the expansion of its regional footprint with the launch of its new Cairo office as the business looks to take advantage of the strengthening Egyptian economy.

     (Photo: )

The new office, which will be based in Cairo”s Garden City, will be led by Mohamed Magdi Omar who joins the business bringing with him a powerful combination of local and sector knowledge from his 20 years of experience in the Egyptian market.

Mohamed Magdi Omar will have full responsibility for the growth of Lockton Egypt, helping launch its market leading proposition and enabling the business to provide on the ground support for its clients.

Wael Khatib, Senior Partner and Chairman (Lockton MENA) said: ‘We are committed to providing our clients with the highest standards of service and part of that means being available to provide face-to-face support and advice wherever they need us. As the economy in Egypt continues to strengthen, we look forward to helping our clients meet their business goals through state of the art insurance and risk management solutions. Our significant growth across MENA has been an exciting journey. We take pride in the wealth and diversity of experience we possess and will continue to evolve and develop our services to ensure they meet clients” needs. Under the leadership of Mohamed Magdi Omar, I am confident the business is well positioned to take advantage of a significant market opportunity.’

Commenting on his new appointment, Mohamed Omar Magdi said, ‘I am delighted to be able to bring together the strength of the Lockton brand with an experienced team that has deep understanding of the local region. Lockton Egypt represents a truly distinct proposition with market leading talent, a global outlook and a commitment to delivering the highest possible service to its clients.’

Lockton MENA has 6 offices across the MENA region.

About Lockton 

More than 6,500 professionals at Lockton provide 50,000 clients around the world with risk management, insurance, and employee benefits consulting services that improve their businesses. From its founding in 1966 in Kansas City, Missouri, Lockton has become the largest privately held insurance broker in the world and 9th largest overall. For nine consecutive years, Business Insurance has recognized Lockton as a ‘Best Place to Work in Insurance.’

Media contacts 

Lena Elfallah
T: +971-4-373-8740

CAIRO, May 1, 2018 /PRNewswire/ —

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o cliccando su "Accetta" permetti il loro utilizzo.